Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

6. Januar 2022 aktualisiert von: Novo Nordisk A/S

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1264

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Argentinien
      • Caba, Argentinien, C1060ABA
        • Novo Nordisk Investigational Site
      • Caba, Argentinien, C1440AAD
        • Novo Nordisk Investigational Site
      • Cordoba, Argentinien, 5000
        • Novo Nordisk Investigational Site
      • Córdoba, Argentinien, 5008
        • Novo Nordisk Investigational Site
  • Bulgarien
      • Kozloduy, Bulgarien, 3320
        • Novo Nordisk Investigational Site
      • Razgrad, Bulgarien, 7200
        • Novo Nordisk Investigational Site
      • Sofia, Bulgarien, 1233
        • Novo Nordisk Investigational Site
      • Sofia, Bulgarien, 1618
        • Novo Nordisk Investigational Site
  • Deutschland
      • Dresden, Deutschland, 01219
        • Novo Nordisk Investigational Site
      • Essen, Deutschland, 45136
        • Novo Nordisk Investigational Site
      • Falkensee, Deutschland, 14612
        • Novo Nordisk Investigational Site
      • Lingen, Deutschland, 49808
        • Novo Nordisk Investigational Site
      • Münster, Deutschland, 48145
        • Novo Nordisk Investigational Site
      • Saint Ingbert-Oberwürzbach, Deutschland, 66386
        • Novo Nordisk Investigational Site
      • Schweinfurt, Deutschland, 97421
        • Novo Nordisk Investigational Site
  • Griechenland
      • Athens, Griechenland, GR-11527
        • Novo Nordisk Investigational Site
      • Athens, Griechenland, 115 25
        • Novo Nordisk Investigational Site
      • Ioannina, Griechenland, 45500
        • Novo Nordisk Investigational Site
      • Larissa, Griechenland, GR-41110
        • Novo Nordisk Investigational Site
      • Thessaloniki, Griechenland, GR-54636
        • Novo Nordisk Investigational Site
      • Thessaloniki, Griechenland, GR-57001
        • Novo Nordisk Investigational Site
      • Thessaloniki, Griechenland, GR-54642
        • Novo Nordisk Investigational Site
      • Thessaloniki, Griechenland, GR-54643
        • Novo Nordisk Investigational Site
  • Italien
      • Catanzaro, Italien, 88100
        • Novo Nordisk Investigational Site
      • Chieti, Italien, 66100
        • Novo Nordisk Investigational Site
      • Cittadella (PD), Italien, 35013
        • Novo Nordisk Investigational Site
      • Milano (MI), Italien, 20132
        • Novo Nordisk Investigational Site
      • Olbia, Italien, 07026
        • Novo Nordisk Investigational Site
      • Palermo, Italien, 90129
        • Novo Nordisk Investigational Site
  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • Novo Nordisk Investigational Site
    • British Columbia
      • Victoria, British Columbia, Kanada, V8V 4A1
        • Novo Nordisk Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • Novo Nordisk Investigational Site
    • Ontario
      • Barrie, Ontario, Kanada, L4N 7L3
        • Novo Nordisk Investigational Site
      • Concord, Ontario, Kanada, L4K 4M2
        • Novo Nordisk Investigational Site
      • Etobicoke, Ontario, Kanada, M9R 4E1
        • Novo Nordisk Investigational Site
      • Hamilton, Ontario, Kanada, L8M 1K7
        • Novo Nordisk Investigational Site
      • Newmarket, Ontario, Kanada, L3Y 5G8
        • Novo Nordisk Investigational Site
      • Thunder Bay, Ontario, Kanada, P7A 4V7
        • Novo Nordisk Investigational Site
      • Toronto, Ontario, Kanada, M4G 3E8
        • Novo Nordisk Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H4T 1Z9
        • Novo Nordisk Investigational Site
  • Korea, Republik von
      • Bucheon, Korea, Republik von, 14647
        • Novo Nordisk Investigational Site
      • Daegu, Korea, Republik von, 42472
        • Novo Nordisk Investigational Site
      • Seongnam-si, Korea, Republik von, 463-707
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 02447
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 03080
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 04516
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 06351
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 08308
        • Novo Nordisk Investigational Site
      • Seoul, Korea, Republik von, 137-701
        • Novo Nordisk Investigational Site
      • Wonju, Korea, Republik von, 26426
        • Novo Nordisk Investigational Site
  • Kroatien
      • Karlovac, Kroatien, 47000
        • Novo Nordisk Investigational Site
      • Osijek, Kroatien, 31 000
        • Novo Nordisk Investigational Site
      • Varazdin, Kroatien, 42 000
        • Novo Nordisk Investigational Site
      • Zagreb, Kroatien, 10 000
        • Novo Nordisk Investigational Site
  • Polen
      • Bialystok, Polen, 15-435
        • Novo Nordisk Investigational Site
      • Skorzewo, Polen, 60-185
        • Novo Nordisk Investigational Site
      • Warsaw, Polen, 00-465
        • Novo Nordisk Investigational Site
      • Warsaw, Polen, 02-793
        • Novo Nordisk Investigational Site
      • Warszawa, Polen, 02-507
        • Novo Nordisk Investigational Site
      • Wroclaw, Polen, 50-381
        • Novo Nordisk Investigational Site
  • Puerto Rico
      • Ponce, Puerto Rico, 00716
        • Novo Nordisk Investigational Site
  • Rumänien
      • Brasov, Rumänien, 500101
        • Novo Nordisk Investigational Site
      • Brasov, Rumänien, 500283
        • Novo Nordisk Investigational Site
      • Bucharest, Rumänien, 13682
        • Novo Nordisk Investigational Site
    • Maramures
      • Baia Mare, Maramures, Rumänien, 430222
        • Novo Nordisk Investigational Site
    • Mures
      • Tirgu Mures, Mures, Rumänien, 540142
        • Novo Nordisk Investigational Site
    • Timis
      • Timisoara, Timis, Rumänien, 300125
        • Novo Nordisk Investigational Site
  • Russische Föderation
      • Arkhangelsk, Russische Föderation, 163045
        • Novo Nordisk Investigational Site
      • Kazan, Russische Föderation, 420073
        • Novo Nordisk Investigational Site
      • Moscow, Russische Föderation, 123448
        • Novo Nordisk Investigational Site
      • Penza, Russische Föderation, 440026
        • Novo Nordisk Investigational Site
      • Saint Petersburg, Russische Föderation, 194291
        • Novo Nordisk Investigational Site
      • Saint-Petersburg, Russische Föderation, 194356
        • Novo Nordisk Investigational Site
      • Tumen, Russische Föderation, 625023
        • Novo Nordisk Investigational Site
      • Voronezh, Russische Föderation, 394018
        • Novo Nordisk Investigational Site
  • Serbien
      • Belgrade, Serbien, 11000
        • Novo Nordisk Investigational Site
      • Kragujevac, Serbien, 34000
        • Novo Nordisk Investigational Site
      • Nis, Serbien, 18000
        • Novo Nordisk Investigational Site
      • Novi Sad, Serbien, 21000
        • Novo Nordisk Investigational Site
      • Zajecar, Serbien, 19000
        • Novo Nordisk Investigational Site
  • Slowakei
      • Kosice, Slowakei, 040 01
        • Novo Nordisk Investigational Site
      • Kysucke Nove Mesto, Slowakei, 024 01
        • Novo Nordisk Investigational Site
      • Lubochna, Slowakei, 03491
        • Novo Nordisk Investigational Site
      • Lucenec, Slowakei, 984 01
        • Novo Nordisk Investigational Site
      • Zilina, Slowakei, 01001
        • Novo Nordisk Investigational Site
  • Spanien
      • Alcobendas, Spanien, 28100
        • Novo Nordisk Investigational Site
      • Almería, Spanien, 04001
        • Novo Nordisk Investigational Site
      • Girona, Spanien, 17007
        • Novo Nordisk Investigational Site
      • La Coruña, Spanien, 15006
        • Novo Nordisk Investigational Site
      • Pozuelo de Alarcon, Spanien, 28223
        • Novo Nordisk Investigational Site
      • Sabadell, Spanien, 08208
        • Novo Nordisk Investigational Site
      • Sevilla, Spanien, 41010
        • Novo Nordisk Investigational Site
      • Sevilla, Spanien, 41003
        • Novo Nordisk Investigational Site
  • Tschechien
      • Hradec Kralove, Tschechien, 500 05
        • Novo Nordisk Investigational Site
      • Plzen, Tschechien, 30100
        • Novo Nordisk Investigational Site
      • Plzen, Tschechien, 32600
        • Novo Nordisk Investigational Site
      • Trutnov, Tschechien, 541 01
        • Novo Nordisk Investigational Site
  • Ukraine
      • Dnipro, Ukraine, 49038
        • Novo Nordisk Investigational Site
      • Kharkiv, Ukraine, 61000
        • Novo Nordisk Investigational Site
      • Kyiv, Ukraine, 03049
        • Novo Nordisk Investigational Site
      • Lviv, Ukraine, 79010
        • Novo Nordisk Investigational Site
      • Ternopil, Ukraine, 46002
        • Novo Nordisk Investigational Site
      • Vinnytsia, Ukraine, 21010
        • Novo Nordisk Investigational Site
  • Vereinigte Staaten
    • California
      • Concord, California, Vereinigte Staaten, 94520
        • Novo Nordisk Investigational Site
      • Fresno, California, Vereinigte Staaten, 93720
        • Novo Nordisk Investigational Site
      • Fullerton, California, Vereinigte Staaten, 92835
        • Novo Nordisk Investigational Site
      • Lancaster, California, Vereinigte Staaten, 93534
        • Novo Nordisk Investigational Site
      • Norco, California, Vereinigte Staaten, 92860
        • Novo Nordisk Investigational Site
      • Sacramento, California, Vereinigte Staaten, 95821
        • Novo Nordisk Investigational Site
      • Ventura, California, Vereinigte Staaten, 93003
        • Novo Nordisk Investigational Site
      • Walnut Creek, California, Vereinigte Staaten, 94598
        • Novo Nordisk Investigational Site
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80246
        • Novo Nordisk Investigational Site
      • Golden, Colorado, Vereinigte Staaten, 80401
        • Novo Nordisk Investigational Site
    • Connecticut
      • Waterbury, Connecticut, Vereinigte Staaten, 06708
        • Novo Nordisk Investigational Site
    • Florida
      • Boynton Beach, Florida, Vereinigte Staaten, 33472
        • Novo Nordisk Investigational Site
      • Bradenton, Florida, Vereinigte Staaten, 34201
        • Novo Nordisk Investigational Site
      • Fort Lauderdale, Florida, Vereinigte Staaten, 33312
        • Novo Nordisk Investigational Site
      • Miami, Florida, Vereinigte Staaten, 33174
        • Novo Nordisk Investigational Site
      • Tampa, Florida, Vereinigte Staaten, 33634
        • Novo Nordisk Investigational Site
    • Georgia
      • Alpharetta, Georgia, Vereinigte Staaten, 30022
        • Novo Nordisk Investigational Site
      • Lawrenceville, Georgia, Vereinigte Staaten, 30046
        • Novo Nordisk Investigational Site
      • Roswell, Georgia, Vereinigte Staaten, 30076
        • Novo Nordisk Investigational Site
    • Hawaii
      • Honolulu, Hawaii, Vereinigte Staaten, 96814
        • Novo Nordisk Investigational Site
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Novo Nordisk Investigational Site
      • Peoria, Illinois, Vereinigte Staaten, 61603
        • Novo Nordisk Investigational Site
      • Springfield, Illinois, Vereinigte Staaten, 62711
        • Novo Nordisk Investigational Site
    • Indiana
      • Valparaiso, Indiana, Vereinigte Staaten, 46383
        • Novo Nordisk Investigational Site
    • Iowa
      • West Des Moines, Iowa, Vereinigte Staaten, 50266
        • Novo Nordisk Investigational Site
    • Kansas
      • Topeka, Kansas, Vereinigte Staaten, 66606
        • Novo Nordisk Investigational Site
    • Kentucky
      • Lexington, Kentucky, Vereinigte Staaten, 40503
        • Novo Nordisk Investigational Site
      • Lexington, Kentucky, Vereinigte Staaten, 40502
        • Novo Nordisk Investigational Site
    • Maryland
      • Rockville, Maryland, Vereinigte Staaten, 20852
        • Novo Nordisk Investigational Site
    • Massachusetts
      • Waltham, Massachusetts, Vereinigte Staaten, 02453
        • Novo Nordisk Investigational Site
      • Worcester, Massachusetts, Vereinigte Staaten, 01655
        • Novo Nordisk Investigational Site
    • Nevada
      • Henderson, Nevada, Vereinigte Staaten, 89052-2649
        • Novo Nordisk Investigational Site
      • Las Vegas, Nevada, Vereinigte Staaten, 89148
        • Novo Nordisk Investigational Site
    • New Hampshire
      • Nashua, New Hampshire, Vereinigte Staaten, 03063
        • Novo Nordisk Investigational Site
    • New York
      • Northport, New York, Vereinigte Staaten, 11768
        • Novo Nordisk Investigational Site
      • West Seneca, New York, Vereinigte Staaten, 14224
        • Novo Nordisk Investigational Site
    • North Carolina
      • Asheville, North Carolina, Vereinigte Staaten, 28803
        • Novo Nordisk Investigational Site
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27514
        • Novo Nordisk Investigational Site
    • Ohio
      • Mentor, Ohio, Vereinigte Staaten, 44060
        • Novo Nordisk Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104-5020
        • Novo Nordisk Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
        • Novo Nordisk Investigational Site
    • South Carolina
      • Greenville, South Carolina, Vereinigte Staaten, 29605-4254
        • Novo Nordisk Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Vereinigte Staaten, 37404
        • Novo Nordisk Investigational Site
      • Chattanooga, Tennessee, Vereinigte Staaten, 37411
        • Novo Nordisk Investigational Site
      • Nashville, Tennessee, Vereinigte Staaten, 37212
        • Novo Nordisk Investigational Site
    • Texas
      • Amarillo, Texas, Vereinigte Staaten, 79106
        • Novo Nordisk Investigational Site
      • Austin, Texas, Vereinigte Staaten, 78731
        • Novo Nordisk Investigational Site
      • Austin, Texas, Vereinigte Staaten, 78749
        • Novo Nordisk Investigational Site
      • Beaumont, Texas, Vereinigte Staaten, 77701
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75230
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75226
        • Novo Nordisk Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75231
        • Novo Nordisk Investigational Site
      • Longview, Texas, Vereinigte Staaten, 75605
        • Novo Nordisk Investigational Site
      • Pearland, Texas, Vereinigte Staaten, 77584
        • Novo Nordisk Investigational Site
      • Round Rock, Texas, Vereinigte Staaten, 78681
        • Novo Nordisk Investigational Site
    • Utah
      • Ogden, Utah, Vereinigte Staaten, 84405
        • Novo Nordisk Investigational Site
    • Vermont
      • Bennington, Vermont, Vereinigte Staaten, 05201
        • Novo Nordisk Investigational Site
      • South Burlington, Vermont, Vereinigte Staaten, 05403
        • Novo Nordisk Investigational Site
    • Virginia
      • Chesapeake, Virginia, Vereinigte Staaten, 23321
        • Novo Nordisk Investigational Site
      • Winchester, Virginia, Vereinigte Staaten, 22601-3834
        • Novo Nordisk Investigational Site
    • Washington
      • Olympia, Washington, Vereinigte Staaten, 98502
        • Novo Nordisk Investigational Site
      • Seattle, Washington, Vereinigte Staaten, 98105
        • Novo Nordisk Investigational Site
      • Spokane, Washington, Vereinigte Staaten, 99201
        • Novo Nordisk Investigational Site
    • Wisconsin
      • Green Bay, Wisconsin, Vereinigte Staaten, 54303
        • Novo Nordisk Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Faster aspart + insulin degludec with or without metformin
Arzneimittel: Faster-acting insulin aspart
Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Arzneimittel: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Arzneimittel: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Aktiver Komparator: NovoRapid/NovoLog + insulin degludec with or without metformin
Arzneimittel: Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Arzneimittel: Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Arzneimittel: Insulin aspart
Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Glycosylated Haemoglobin (HbA1c)
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in 1-hour PPG Increment
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in 1,5-anhydroglucitol
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG)
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)
Zeitfenster: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)
Zeitfenster: 16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG [meal test]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Week 0, week 16
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.
Week 0, week 16
Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile
Zeitfenster: Week 0, week 16
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements
Zeitfenster: Week 0, week 16
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)
Zeitfenster: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)
Zeitfenster: 16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Total Bolus Insulin Dose: in Units/Day
Zeitfenster: 16 weeks from randomisation
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Bolus Insulin Dose: in Units/kg/Day
Zeitfenster: 16 weeks from randomisation
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/Day
Zeitfenster: 16 weeks from randomisation
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/kg/Day
Zeitfenster: 16 weeks from randomisation
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units
Zeitfenster: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units/kg
Zeitfenster: 16 weeks from randomisation
Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline
Zeitfenster: Week 0, week 16
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Number of Treatment Emergent Adverse Events
Zeitfenster: Weeks 0-16
Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Injection Site Reactions
Zeitfenster: Weeks 0-16
Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
Zeitfenster: Weeks 0-16

ADA classification of hypos:

  1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.
  2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms.
  3. Asymptomatic: PG ≤3.9 mmol/L without symptoms.
  4. Probable symptomatic: No measurement with symptoms.
  5. Pseudo: PG >3.9 mmol/L with symptoms.
  6. Unclassifiable.

NN classification of hypos:

  1. BG confirmed: PG <3.1 mmol/L with/without symptoms.
  2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with symptoms.
  3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with/without symptoms.
  4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
Zeitfenster: Weeks 0-16
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
Zeitfenster: Weeks 0-16
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
Zeitfenster: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
Zeitfenster: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
Zeitfenster: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
Zeitfenster: Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Change From Baseline in Physical Examination
Zeitfenster: Week 0, week 16
Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central & Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin
Week 0, week 16
Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure
Zeitfenster: Week 0, week 16
Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Vital Signs: Pulse
Zeitfenster: Week 0, week 16
Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Electrocardiogram (ECG)
Zeitfenster: Week 0, week 16
Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Fundoscopy/Fundus Photography
Zeitfenster: Week 0, week 16
Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haematocrit
Zeitfenster: Week 0, week 16
Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haemoglobin
Zeitfenster: Week 0, week 16
Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Leukocytes
Zeitfenster: Week 0, week 16
Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Thrombocytes
Zeitfenster: Week 0, week 16
Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Erythrocytes
Zeitfenster: Week 0, week 16
Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)
Zeitfenster: Week 0, week 16
Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alkaline Phosphatase
Zeitfenster: Week 0, week 16
Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)
Zeitfenster: Week 0, week 16
Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Albumin
Zeitfenster: Week 0, week 16
Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Creatinine
Zeitfenster: Week 0, week 16
Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Potassium
Zeitfenster: Week 0, week 16
Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Sodium
Zeitfenster: Week 0, week 16
Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Bilirubin
Zeitfenster: Week 0, week 16
Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Protein
Zeitfenster: Week 0, week 16
Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Weight
Zeitfenster: Week 0, week 16
Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Mass Index (BMI)
Zeitfenster: Week 0, week 16
Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Novo Nordisk A/S

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. September 2017

Primärer Abschluss (Tatsächlich)

7. Januar 2019

Studienabschluss (Tatsächlich)

29. Januar 2019

Studienanmeldedaten

Zuerst eingereicht

29. August 2017

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. August 2017

Zuerst gepostet (Tatsächlich)

31. August 2017

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. Januar 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. Januar 2022

Zuletzt verifiziert

1. Januar 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • NN1218-4113
  • U1111-1180-0636 (Andere Kennung: World Health Organization (WHO))
  • 2016-000878-38 (Registrierungskennung: European Medicines Agency (EudraCT))

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

Ja

Beschreibung des IPD-Plans

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Diabetes mellitus, Typ 2

Klinische Studien zur Faster-acting insulin aspart

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Bangladesh

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren